X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

By Stephen J. Ubl  |    January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

By Lauren Neves  |    October 20, 2016
The value of recent advances in non-small cell lung cancer (NSCLC) is undeniable. NSCLC is a devastating illness – 17.7 percent of lung cancer patients survive only five years following their...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

4 recommendations for ICER

By Lauren Neves  |    September 26, 2016
For years, PhRMA has supported policies that ensure health care decisions are grounded in the best available evidence. In our policy solutions for delivering innovative treatments to patients...   Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

By Holly Campbell  |    September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...   Read More

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

By Michelle Drozd  |    September 14, 2016
As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health...   Read More

ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

By Holly Campbell  |    September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...   Read More

Study finds actual cost of 14 new medicines is billions less than predicted

By Holly Campbell  |    August 16, 2016
In case you missed it, a forthcoming study will disprove – once again – misleading claims pharmacy benefit managers and insurers, among others, routinely make about spending on new innovative...   Read More

ICYMI: ICER solicits feedback on its value assessment framework

By Randy Burkholder  |    July 28, 2016
In case you missed it, the Institute for Clinical and Economic Review (ICER) is seeking suggestions to improve its value assessment framework prior to its re-release in 2017. For the past two...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates